SOPHiA GENETICS SA (NASDAQ:SOPH) Given Consensus Recommendation of “Hold” by Brokerages

Posted by on Aug 17th, 2026

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) have been assigned an average rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.00.

Several equities research analysts recently issued reports on the stock. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research upped their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st.

Get Our Latest Research Report on SOPH

Insider Buying and Selling

In related news, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the sale, the insider owned 590,887 shares in the company, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the sale, the chief executive officer directly owned 3,601,493 shares of the company’s stock, valued at $20,888,659.40. This represents a 1.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 318,592 shares of company stock valued at $1,952,315. 4.88% of the stock is owned by insiders.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently modified their holdings of SOPH. Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth about $49,000. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS in the 4th quarter valued at about $49,000. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter valued at about $50,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS during the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS during the fourth quarter worth approximately $55,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $7.50 on Monday. The firm has a market capitalization of $629.17 million, a P/E ratio of -6.52 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm’s fifty day moving average price is $5.89 and its two-hundred day moving average price is $5.22. SOPHiA GENETICS has a 1 year low of $3.10 and a 1 year high of $7.88.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, research analysts anticipate that SOPHiA GENETICS will post -0.77 EPS for the current year.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Featured Stories

Analyst Recommendations for SOPHiA GENETICS (NASDAQ:SOPH)

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.